Startups
Eye2Gene
London, United Kingdom
Eye2Gene is a London precision-ophthalmology company combining retinal imaging, genomics and machine learning to identify likely genetic causes of inherited retinal disease. Its software prioritises candidate genes, measures imaging biomarkers and supports diagnosis, clinical-trial recruitment and gene-therapy development. The 2025 Nature Machine Intelligence study provides retrospective research validation; it does not establish universal clinical accuracy or regulatory approval. An active Innovate UK project aims to obtain UKCA/CE approval before clinical deployment. The active legal entity is Eye2Gene Limited, UK company 11534583, incorporated on 23 August 2018. UCL Ventures and the issuer date its commercial spinout to 2026; that milestone is distinct from legal incorporation. Phenopolis Limited (11541164) is a separate software company sharing researchers, with no verified rename or merger. The technology originated in UCL Institute of Ophthalmology and Moorfields research. Published leadership includes CEO/co-founder Nikolas Pontikos, CTO/co-founder Ismail Moghul, Chief AI Officer/co-founder William Woof and CMO/co-founder Michel Michaelides. Elis Yalman manages projects and medical-science liaison. The issuer's 2026 staff introductions also name Errolson Gonito, Alan Sousa da Silva, Judith McCarron, Saumya Agrawal, Oksana Krykun, commercial adviser Bruce Hellman and commercial intern Andrés Edwards. Saumya's October 2026 move from Founder Associate to part-time communications is qualified separately. Public profile-member counts and research coauthorship are not treated as undisclosed employees. The corrected statutory share-allotment filing records cash shares issued during 23–30 March 2026: 328,945 A ordinary shares at GBP 3.04 and 80,000 ordinary shares at GBP 0.00001, totalling GBP 999,993.60. A separate 6–20 July 2026 allotment records 90,570 A ordinary shares at GBP 3.04, totalling GBP 275,332.80. These are statutory subscription periods, with series labels, individual buyers and exact closing days undisclosed. Exact cents remain in evidence because the structured Money field supports whole units. The original March SH01 was replaced on 3 August 2026. Innovate UK's official project 10189359 records a GBP 298,345 grant offer to Eye2Gene Limited for regulatory approval, active May 2026–November 2027. GBP 662,989 is project cost, not the grant; an offer is not proof of bank disbursement. Twin Path Ventures' exact-domain portfolio confirms an undated investment affiliation without allocating it to either statutory allotment. Earlier NIHR and charity awards supported academic research and are not automatically company cash. Support logos alone do not establish paid equity checks by KQ Labs, UCLB, AWS, Adeline or Cambridge Angels. Secondary claims of a November 2025 USD 921,000 seed and USD 2.73 million cumulative financing remain unverified.
Founded 2018
Team
 Alan Sousa da SilvaSenior Scientific Software Developer |
Andrés EdwardsCommercial Strategy and Business Development Intern (published2026) |
 Bruce HellmanCommercial Advisor |
 Elis YalmanProject Manager and Medical Science Liaison |
 Errolson GonitoFrontend Developer |
 Ismail MoghulDirector (Eye2Gene Limited) · Chief Technology Officer, Co-founder |
Judith McCarronRegulatory Affairs and Quality Lead |
 Michel MichaelidesDirector (Eye2Gene Limited) · Chief Medical Officer, Co-founder |
 Nikolas PontikosDirector (Eye2Gene Limited) · Company Secretary (Eye2Gene Limited) · Chief Executive Officer, Co-founder |
 Oksana KrykunFounder Associate |
Saumya AgrawalHead of Communications (part-time; published October2026 transition) · Founder Associate (historical; prior to October2026 communications transition) |
 William WoofDirector (Eye2Gene Limited) · Chief AI Officer, Co-founder |